HUMDF.US Hua Medicine (Shanghai) Ltd

Healthcare Pharmaceuticals USA Stocks
0.3036 USD
Close of Nov 15, 2026
0.2935 0.5000
Market cap
USD 303M
P/E
-
P/B
2.04x
ROE
-12.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is HUMDF.US undervalued?

Graham number

The Graham number of Hua Medicine (Shanghai) Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hua Medicine (Shanghai) Ltd fundamental analysis

No fundamental analysis for Hua Medicine (Shanghai) Ltd yet.

Hua Medicine (Shanghai) Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hua Medicine (Shanghai) Ltd

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insuli…

Full company profile